



## Orion Pharma Limited

Registered Office: Orion House, 153-154 Tejgaon I/ A,  
Dhaka - 1208

### Un-Audited 3<sup>rd</sup> Quarterly (Q3) Financial Statements

This is to inform all concerned that, in Board Meeting held on April 29, 2025 at 4:00 p.m. in the registered office at Orion House, 153-154 Tejgaon I/ A, Dhaka - 1208, the Board of Directors of Orion Pharma Limited has adopted its Un- audited 3<sup>rd</sup> Quarterly (Q3) Financial Statements for the period ended March 31, 2025:

For the Period		July-March 2025	July-March 2024	January- March 2025	January- March 2024
Consolidated Earnings Per Share (EPS) - Q3	:	BDT (0.18)	BDT 1.65	BDT 0.02	BDT 0.42
Consolidated Net Operating Cash Flow Per Share (NOCFPS) - Q3	:	BDT 5.27	BDT 3.09	--	--
Particulars		March 31, 2025		June 30, 2024	
Consolidated Net Asset Value (NAV) per Share (Including Revaluation Surplus)	:	BDT 89.18		BDT 92.05	
Consolidated Net Asset Value (NAV) per Share (Excluding Revaluation Surplus)	:	BDT 81.42		BDT 84.27	

Dated: April 29, 2025  
Tejgaon, Dhaka

By the order of the Board  
Sd/-  
**Md. Ferdous Jaman**  
Company Secretary